invas
aspergillosi
ia
opportunist
infect
caus
aspergillu
ubiquit
present
airborn
pathogen
mold
grow
number
studi
suggest
major
host
genet
compon
diseas
suscept
evalu
whether
singlenucleotid
polymorph
within
rela
relb
rel
gene
influenc
risk
ia
popul
highrisk
patient
ia
nonia
recruit
collabor
effort
involv
aspbiom
consortium
four
european
clinic
institut
signific
overal
associ
select
snp
risk
ia
found
larg
cohort
although
hematopoiet
stem
cell
transplant
hsct
stratifi
analysi
reveal
carrier
genotyp
sixfold
increas
risk
develop
infect
compar
carri
c
allel
rec
ci
p
associ
variant
ia
risk
reach
signific
experimentwid
signific
threshold
addit
found
associ
aatc
ggtc
haplotyp
includ
risk
allel
decreas
risk
ia
magnitud
associ
similar
one
observ
singlesnp
analysi
et
al
gene
polymorph
ia
indic
haplotyp
effect
ia
risk
like
due
snp
final
evid
signific
interact
among
genet
marker
test
risk
ia
found
result
suggest
snp
studi
gene
clinic
relev
impact
risk
develop
ia
invas
aspergillosi
ia
opportunist
infect
caus
aspergillu
ubiquit
present
airborn
pathogen
mold
grow
number
studi
suggest
major
host
genet
compon
diseas
suscept
evalu
whether
singlenucleotid
polymorph
within
rela
relb
rel
gene
influenc
risk
ia
popul
highrisk
patient
ia
nonia
recruit
collabor
effort
involv
aspbiom
consortium
four
european
clinic
institut
signific
overal
associ
select
snp
risk
ia
found
larg
cohort
although
hematopoiet
stem
cell
transplant
hsct
stratifi
analysi
reveal
carrier
genotyp
sixfold
increas
risk
develop
infect
compar
carri
c
allel
rec
ci
p
associ
variant
ia
risk
reach
signific
experimentwid
signific
threshold
addit
found
associ
aatc
ggtc
haplotyp
includ
risk
allel
decreas
risk
ia
magnitud
associ
similar
one
observ
singlesnp
analysi
indic
haplotyp
effect
ia
risk
like
due
snp
final
evid
signific
interact
among
genet
marker
test
risk
ia
found
result
suggest
snp
studi
gene
clinic
relev
impact
risk
develop
ia
invas
aspergillosi
ia
opportunist
infect
often
caus
speci
aspergillu
common
saprophyt
filament
fungu
ubiquit
present
environ
life
initi
estim
around
million
patient
worldwid
high
risk
develop
ia
everi
year
patient
develop
infect
annual
despit
substanti
improv
efficaci
newli
develop
antifung
drug
mainli
azol
alon
combin
antifung
drug
ia
continu
lifethreaten
infect
increas
proport
immunocompromis
critic
ill
subject
neofyto
et
al
steinbach
et
al
ia
frequent
encount
patient
intens
care
meersseman
et
al
solid
organ
transplant
unit
singh
et
al
also
among
patient
undergo
allogen
hematopoiet
stem
cell
transplant
allohsct
diagnos
either
acut
myeloid
leukemia
aml
acut
lymphoid
leukemia
receiv
highdos
chemotherapi
regimen
steinbach
et
al
neofyto
et
al
b
although
major
clinic
risk
factor
ia
identifi
kousha
et
al
manag
highrisk
patient
improv
optim
prevent
strategi
earli
initi
antifung
prophylaxi
mortal
rate
ia
remain
still
today
unaccept
high
neofyto
et
al
steinbach
et
al
karthau
buchheidt
observ
find
suggest
addit
factor
may
contribut
risk
develop
ia
regard
grow
number
studi
suggest
host
genet
polymorph
within
near
immunerel
gene
may
contribut
determin
risk
develop
infect
kesh
et
al
sainz
et
al
sainz
et
al
b
sainz
et
al
b
sainz
et
al
bochud
et
al
mezger
et
al
ramaprakash
et
al
cunha
et
al
cunha
et
al
cunha
et
al
chai
et
al
grube
et
al
stapper
et
al
wojtowicz
et
al
b
interestingli
substanti
proport
suscept
marker
identifi
date
ia
locat
gene
directli
indirectli
implic
activ
nuclear
factorkappa
b
signal
pathway
suggest
relev
role
biolog
rout
determin
risk
develop
fungal
infect
particular
report
singl
nucleotid
polymorph
snp
within
tolllik
receptor
tlr
mambula
et
al
kesh
et
al
bochud
et
al
pamer
ramaprakash
et
al
carvalho
et
al
grube
et
al
ctype
lectin
cunha
et
al
chai
et
al
sainz
et
al
cunha
et
al
tumor
necrosi
factor
receptor
tnfr
sainz
et
al
sainz
et
al
pathogen
recognit
receptor
prr
often
culmin
activ
pathway
may
render
patient
suscept
develop
ia
base
find
also
demonstr
rel
relb
crel
gene
may
form
homoand
heterodim
regul
activ
canon
noncanon
pathway
moynagh
gilmor
hoffmann
et
al
schlitzer
et
al
et
al
also
immun
respons
boddick
et
al
hypothes
presenc
common
genet
polymorph
within
rela
relb
rel
gene
might
influenc
risk
develop
ia
highrisk
patient
thu
aim
present
studi
investig
relationship
singl
nucleotid
polymorph
within
gene
risk
ia
also
determin
whether
variant
could
interact
modifi
risk
develop
infect
eight
hundr
thirtyfour
highrisk
european
caucasian
patient
undergo
allohsct
diagnos
acut
myeloid
leukemia
aml
acut
lymphoid
leukemia
receiv
intens
remissioninduct
chemotherapi
recruit
casecontrol
populationbas
studi
et
al
three
hundr
thirtyf
patient
ascertain
aspbiom
consortium
http
www
aspbiomicseu
wherea
patient
collect
two
spanish
medic
institut
univers
hospit
salamanca
clinic
univers
hospit
valencia
spanish
multicent
clinic
trial
pcraga
eu
clinic
trial
number
aguado
et
al
addit
patient
recruit
two
italian
medic
institut
cattolica
del
cuor
rome
univers
modena
reggio
emilia
aou
policlinico
modena
patient
total
patient
diagnos
proven
probabl
ia
accord
updat
eortcmsg
criteria
de
pauw
et
al
wherea
remain
patient
show
sign
fungal
infect
fourteen
polymorph
within
rela
relb
rel
gene
select
genotyp
whole
popul
tabl
snp
select
base
previous
report
associ
cancer
curtin
et
al
et
al
han
et
al
slatteri
et
al
seufert
et
al
wang
et
al
immunerel
diseas
includ
infect
chen
et
al
chen
et
al
gregersen
et
al
trynka
et
al
eyr
et
al
et
al
bow
et
al
ellinghau
et
al
ali
et
al
leung
et
al
pan
et
al
also
potenti
function
accord
haploreg
http
wwwbroadinstituteorg
mammalshaploreghaploregphp
encod
annot
data
http
genomeucsceduencod
genotyp
select
polymorph
carri
genyo
center
genom
oncolog
research
pfizerunivers
granadaandalusian
region
govern
granada
spain
use
kaspar
r
assay
lgc
genom
hoddesdon
uk
accord
manufactur
instruct
intern
qualiti
control
sampl
randomli
select
includ
duplic
concord
origin
duplic
sampl
snp
call
rate
snp
except
snp
exclud
analysi
hardyweinberg
equilibrium
hwe
test
perform
control
group
nonia
patient
standard
observedexpect
chisquar
logist
regress
analysi
adjust
age
sex
countri
origin
allohsct
underli
diseas
prophylaxi
statu
use
assess
main
effect
select
snp
ia
risk
also
perform
genehsct
interact
analys
determin
whether
associ
snp
ia
similar
magnitud
hsct
highest
risk
nonhsct
patient
although
select
variabl
adjust
base
wellestablish
risk
factor
ia
partial
avail
data
regard
prophylaxi
statu
type
chemotherapi
immunosuppress
drug
hsct
hla
mismatch
hsct
cmv
statu
allow
us
assess
impact
factor
genet
associ
test
statist
power
overal
hsctstratifi
analys
estim
use
quanto
softwar
http
hydrauscedugx
test
conduct
use
statist
softwar
spss
stata
mac
order
account
multipl
comparison
calcul
adjust
signific
level
use
meff
method
nyholt
also
consid
number
inherit
model
test
codomin
domin
recess
logaddit
thu
signific
threshold
use
main
effect
analysi
independ
genet
marker
inherit
model
haplotyp
block
construct
genotyp
data
nonia
control
group
use
snptool
http
www
dkfzdedemolgenepidemiologytoolssnptoolhtml
chen
et
al
haploview
softwar
select
polymorph
within
locu
linkag
disequilibrium
ensur
variant
repres
independ
variabl
signal
supplementari
figur
addit
analysi
base
singl
snp
perform
haplotyp
frequenc
estim
haplotyp
associ
analysi
use
snpstat
http
bioinfoiconcologia
netsnpstat
haplotyp
frequenc
determin
use
expectationmaxim
em
algorithm
minimum
haplotyp
frequenc
set
therefor
assess
associ
common
haplotyp
also
assess
whether
select
polymorph
correl
mrna
express
publicli
avail
eqtl
igv
browser
primari
cell
http
wwwgtexportalorghom
use
haploreg
data
also
interest
test
whether
snp
could
interact
modifi
risk
ia
use
multifactor
dimension
reduct
mdr
softwar
detail
descript
mdr
method
report
elsewher
ritchi
et
al
moor
crossvalid
analysi
exhaust
search
permut
test
use
confirm
best
interact
model
mdr
model
consid
statist
signific
p
p
sign
statist
signific
particular
model
reevalu
use
permut
test
compar
observ
test
balanc
accuraci
expect
null
hypothesi
associ
use
mdr
permut
test
modul
alpha
interact
visual
construct
interact
dendrogram
accord
method
describ
moor
et
al
moor
mdr
softwar
mdr
permut
test
modul
opensourc
freeli
avail
http
wwwepistasisorg
populationbas
casecontrol
studi
total
hematolog
patient
recruit
demograph
clinic
characterist
patient
summar
tabl
ia
nonia
patient
similar
age
male
patient
prone
develop
ia
femal
malefemal
ratio
vs
p
hsct
common
equal
distribut
ia
nonia
group
vs
underli
diseas
hematolog
disord
also
uniform
group
tabl
expect
patient
without
prophylaxi
prone
develop
ia
compar
patient
take
antifung
drug
vs
tabl
snp
hardyweinberg
control
group
except
rel
exclud
analys
nonia
p
allel
genotyp
frequenc
select
snp
line
report
hapmap
logist
regress
analysi
adjust
age
sex
countri
origin
allohsct
underli
diseas
show
none
select
snp
significantli
associ
risk
ia
accord
codomin
domin
recess
logaddit
model
inherit
tabl
addit
although
prophylaxi
statu
partial
avail
popul
n
signific
chang
associ
estim
observ
clinic
variabl
includ
covari
adjust
data
shown
signific
associ
crel
relb
polymorph
ia
risk
also
found
allohsctrestrict
analysi
consid
donor
genotyp
ia
episod
occur
transplant
tabl
although
statist
power
limit
supplementari
tabl
found
fairli
weak
associ
genotyp
risk
develop
infect
nomin
signific
level
p
carrier
genotyp
show
sixfold
increas
risk
develop
ia
compar
patient
carri
wild
type
callel
rec
ci
p
interestingli
found
presenc
minor
allel
strongli
correl
mrna
express
level
whole
blood
sampl
epsteinbarr
viru
ebv
transform
lymphocyt
p
p
respect
suggest
possibl
function
role
polymorph
base
interest
result
decid
explor
potenti
function
impact
polymorph
use
haploreg
encod
annot
data
analysi
reveal
snp
resid
strong
enhanc
near
activ
promot
might
constitut
regulatori
element
addit
analysi
show
intron
polymorph
predict
chang
bind
motif
hmgiy
protein
implic
transcript
regul
multipl
innat
adapt
immunerel
gene
liu
et
al
hayden
et
al
falkenberg
johnston
line
find
suggest
function
role
variant
also
found
snp
map
among
promot
enhanc
histon
mark
differ
primari
tcell
subtyp
treg
differ
origin
peripher
blood
hematopoiet
stem
cell
cord
blood
etc
also
primari
bcell
natur
killer
cell
monocyt
although
point
tempt
specul
snp
might
play
role
modul
risk
develop
ia
like
regul
mrna
express
level
associ
snp
ia
risk
remain
signific
correct
multipl
test
p
tabl
therefor
requir
confirm
agreement
singlesnp
analysi
haplotyp
associ
analysi
show
fairli
weak
associ
aatc
ggtc
haplotyp
includ
risk
allel
decreas
risk
ia
howev
associ
similar
magnitud
one
observ
snp
singlesnp
analysi
ci
p
ci
tabl
suggest
haplotyp
effect
due
intron
variant
final
given
involv
physiolog
complex
activ
signal
pathway
role
complex
transcript
activ
boddick
et
al
also
decid
investig
whether
snp
might
interact
modifi
risk
ia
result
mdr
analysi
evalu
possibl
combin
among
snp
shown
tabl
figur
best
model
suggest
interact
rel
rel
snp
synergist
increas
risk
develop
ia
ta
p
sign
although
model
best
predict
ia
present
high
cross
valid
consist
cvc
remain
statist
signific
follow
permut
test
p
addit
found
signific
interact
model
includ
snp
increas
risk
get
infect
ta
p
sign
interact
model
also
fail
retain
statist
signific
permut
test
p
tabl
none
best
model
includ
snp
pathway
implic
foster
wide
varieti
physiolog
process
immun
cell
turnov
hayden
et
al
inflamm
karin
greten
tcell
differenti
treg
subset
oh
ghosh
dc
matur
burkli
et
al
abe
et
al
cell
apoptosi
wang
et
al
karin
greten
cell
adhes
chen
et
al
lockyer
et
al
chiang
et
al
angiogenesi
beink
ley
presenc
fungal
pathogen
aspergillu
fumigatu
canon
pathway
involv
complex
activ
membran
pattern
recognit
receptor
prr
tolllik
receptor
tlr
mambula
et
al
bellocchio
et
al
roeder
et
al
ctype
lectin
receptor
clr
et
al
leibundgutlandmann
et
al
gringhui
et
al
rivera
et
al
saijo
iwakura
cytokin
receptor
tnfr
bozza
et
al
solubl
prr
like
pentraxin
garlanda
et
al
lead
immedi
secret
proinflammatori
cytokin
tnf
nicholson
et
al
roeder
et
al
chemokin
shahan
et
al
phadk
mehrad
reid
et
al
reactiv
oxygen
speci
ro
superoxid
hydroxyl
radic
nitric
oxid
philipp
et
al
chiang
et
al
also
express
specif
immun
receptor
cell
surfac
adhes
molecul
eselectin
akira
et
al
chiang
et
al
gringhui
et
al
addit
bind
fungal
compound
ctype
lectin
activ
certain
tnf
famili
cytokin
baff
observ
fungal
infect
lead
activ
noncanon
pathway
implic
bcell
dc
matur
hu
et
al
sun
cell
develop
powolnybudnicka
et
al
also
control
express
wide
rang
immunerel
gene
geijtenbeek
gringhui
vallabhapurapu
crossvalid
permut
test
use
identifi
best
model
possibl
twoway
snp
interact
test
use
crossvalid
exhaust
search
model
highest
test
balanc
accuraci
ta
cross
valid
consist
cvc
select
best
model
statist
signific
evalu
sign
test
confirm
use
permut
test
compar
observ
test
balanc
accuraci
expect
null
hypothesi
associ
use
mdr
permut
test
modul
alpha
permut
test
ta
ta
ta
ta
figur
interact
dendrogram
interact
dendrogram
reveal
signific
interact
among
studi
snp
modul
risk
ia
karin
plato
et
al
hand
recent
suggest
exist
loop
regul
pathway
cell
prolifer
boddick
et
al
role
modul
differenti
differ
dc
et
al
immun
respons
fumigatu
schlitzer
et
al
consid
central
role
pathway
immun
respons
fumigatu
oh
ghosh
schlitzer
et
al
william
et
al
studi
suggest
genet
host
factor
may
account
differ
suscept
ia
ok
et
al
van
der
velden
et
al
decid
investig
link
genet
polymorph
within
rela
relb
rel
gene
risk
ia
spite
grow
number
studi
assess
role
genet
polymorph
within
prr
dcsign
kesh
et
al
bochud
et
al
pamer
cunha
et
al
cunha
et
al
cunha
et
al
chai
et
al
sainz
et
al
grube
et
al
wojtowicz
et
al
cytokin
ifng
sainz
et
al
sainz
et
al
et
al
receptor
sainz
et
al
sainz
et
al
et
al
determin
suscept
invas
fungal
infect
first
studi
attempt
evalu
impact
polymorph
within
rela
relb
rel
gene
risk
develop
ia
data
show
signific
overal
associ
select
snp
ia
infect
best
result
associ
snp
increas
risk
ia
hsct
patient
suggest
weak
effect
locu
risk
ia
might
becom
evid
patient
profound
degre
immunosuppress
howev
despit
potenti
interest
result
evid
support
function
role
variant
regul
mrna
express
therebi
modul
pathway
boddick
et
al
immun
respons
schlitzer
et
al
et
al
associ
variant
remain
signific
experimentwid
signific
threshold
suggest
associ
polymorph
ia
could
due
chanc
haplotyp
analysi
show
small
effect
common
haplotyp
ia
risk
magnitud
effect
suggest
observ
associ
like
due
snp
rather
combin
effect
snp
addit
evalu
whether
signific
interact
among
snp
analyz
observ
consist
interact
model
could
affect
risk
develop
ia
conclus
casecontrol
studi
provid
strong
evid
relationship
polymorph
within
crel
relb
gene
ia
risk
nonetheless
given
limit
statist
power
hsctstratifi
analysi
detect
odd
ratio
snp
frequenc
domin
model
evid
suggest
function
role
snp
dismiss
possibl
small
still
real
effect
variant
haplotyp
risk
ia
hsct
patient
futur
casecontrol
populationbas
studi
conduct
larger
hsct
popul
warrant
evalu
whether
locu
may
role
determin
suscept
ia
studi
protocol
approv
local
ethic
review
board
particip
center
written
inform
consent
obtain
patient
inclus
accord
declar
helsinki
ethic
approv
studi
provid
de
e
clinica
ceic
virgen
de
la
niev
hospit
granada
univers
hospit
salamanca
salamanca
clinic
univers
hospit
valencia
valencia
centro
nacion
de
microbiologia
pcraga
trial
regist
clinicaltrialsgov
eudract
ethic
approv
also
provid
subcomissao
de
etica
para
ciencia
da
vida
e
saud
js
analys
data
mj
js
draft
manuscript
author
read
approv
final
version
manuscript
studi
support
grant
fondo
de
investigacion
sanitaria
instituto
de
salud
carlo
iii
madrid
spain
eranet
pathogenom
ministerio
de
ciencia
e
madrid
spain
collabor
research
center
transregio
funginet
austrian
scienc
fundat
fwf
para
e
tecnologia
fct
cofund
programa
operacion
region
nort
novo
nort
quadro
de
nacion
qren
fundo
europeu
de
desenvolvimento
region
feder
projeto
la
agostinho
carvalho
cristina
cunha
support
para
e
tecnologia
fct
portug
respect
pcraga
trial
support
unrestrict
grant
pfizer
involv
control
collect
analysi
interpret
data
write
report
decis
submit
paper
public
studi
also
support
astella
pharma
inc
donat
consuelo
moreno
acut
myeloid
leukemia
survivor
supplementari
materi
articl
found
onlin
http
supplementari
tabl
